Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q1 2025 Earnings Call Transcript
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q1 2025 Earnings Call Transcript May 8, 2025Iovance Biotherapeutics, Inc. misses on earnings expectations.
Iovance Biotherapeutics Inc. (IOVA)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Bayforest Capital Theodoros Tsagaris | 0 | $0 | 0% | |
| 2. | Neo Ivy Capital Renee Yao | 0 | $0 | 0% | |
| 3. | Bailard Inc Thomas Bailard | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $9.15 | 250,000 | Director | 320,150 | 2024-02-20 | Filing | |
| $9.15 | 32,000 | Director | 54,000 | 2024-02-20 | Filing | |
| $9.15 | 5,000,000 | Director | 28,067,333 | 2024-02-20 | Filing | |
| $5.56 | 10,000 | Director | 248,633 | 2023-09-18 | Filing | |
| $5.30 | 5,000,000 | Director | 23,067,333 | 2023-09-15 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $10.06 | 50,000 | Director | 7,500 | 2024-11-12 | Filing | |
| $8.71 | 20,500 | Director | 100,000 | 2016-08-25 | Filing | |
| $9.10 | 33,500 | Director | 120,500 | 2016-08-24 | Filing | |
| $9.11 | 54,000 | Director | 100,000 | 2016-08-22 | Filing | |
| $7.13 | 16,500 | Director | 154,000 | 2015-09-08 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 27,777,778 | $92,500,000 | 0% | |
| 2. | 24,314,578 | $80,967,543 | 0% | |
| 3. | 5,571,902 | $18,554,434 | 0% | |
| 4. | 4,694,122 | $15,631,427 | 0.01% | |
| 5. | 1,847,741 | $6,152,978 | 0% |
News See All
11 Most Promising Penny Stocks According to Analysts
Solus’ Dan Greenhaus, and Invesco's Brian Levitt together appeared on CNBC's 'Closing Bell' on April 15 to talk about tariffs, market uncertainty, and risk concerns.
13 Best Biotech Penny Stocks to Buy According to Hedge Funds
Peter Marks's departure from the FDA has left innovators concerned regarding the current state of the review program at the FDA. Marks had impacts on two key areas.
10 Stocks Under $10 that Will Triple
As we delve into the discussion on stocks that will triple, we must shed light on the U.S.
10 Most Oversold Penny Stocks to Buy According to Analysts
In February 2025, Wellington Management published its outlook for small-cap stocks in 2025.
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q4 2024 Earnings Call Transcript
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q4 2024 Earnings Call Transcript February 27, 2025Iovance Biotherapeutics, Inc. reports earnings inline with expectations.
Billionaire Joseph Edelman's Top 10 Long-Term Stock Picks
Joseph Edelman is a renowned figure in the investment world, recognized for his expertise in biotechnology and healthcare investing.
10 Firms End 2024 Stronger With Impressive Gains
The Dow Jones Industrial Average dipped by 0.07 percent, the S&P 500 shed 0.43 percent, and the Nasdaq Composite declined by 0.90 percent.
10 Most Promising Cancer Stocks According to Hedge Funds
According to the World Health Organization (WHO), cancer remains one of the leading causes of death globally, responsible for nearly 10 million deaths in 2020, or about one in six deaths worldwide.
12 NASDAQ Stocks with Biggest Upside Potential According to Analysts
Potomac Wealth Advisors president Mark Avallone joined CNBC's 'The Exchange' on November 16 to discuss where he sees investing opportunities following Trump's election.
Billionaire Hedge Funds
